Transcatheter Valve Repair System Market Report 2025

The transcatheter valve repair system market size has grown strongly in recent years. It will grow from $5.08 billion in 2024 to $5.48 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to growing cardiovascular disease rates, surgical limitations, initial transcatheter valve success, research and development investments, physician adoption and training.

The transcatheter valve repair system market size is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to expanded indications, aging population, value-based healthcare initiatives, patient-centric care models, next-generation device development. Major trends in the forecast period include long-term durability focus, healthcare system integration, data-driven precision medicine, remote and robotic-assisted interventions, hybrid procedures.

The anticipated increase in the occurrence of heart diseases is set to drive the growth of the transcatheter valve repair system market in the foreseeable future. Heart disease, affecting either the blood vessels or the heart itself, can be addressed using transcatheter devices, which replace a faulty aortic valve with an artificial one, particularly in the treatment of aortic valve disease. As of December 2022, data released by the New York government reveals that heart disease claims the lives of approximately 697,000 people annually in the United States, accounting for 1 in 5 fatalities. Moreover, around 805,000 Americans experience a heart attack each year, with 605,000 being first-time occurrences and 200,000 resulting from previous heart attacks. Consequently, the increasing incidence of heart disease is a driving factor in the transcatheter valve repair system market's growth.

The increasing geriatric population worldwide is expected to drive the growth of the transcatheter valve repair system market in the coming years. The geriatric population refers to individuals who are generally 65 years of age or older. Transcatheter valve repair systems provide less invasive treatment options, which are particularly advantageous for older patients who may face higher risks during surgery. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a US-based department of the UN Secretariat, projected that the number of individuals aged 65 and older globally will more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. Thus, the rise in the geriatric population around the world will propel the growth of the transcatheter valve repair system market.

Product innovation is a prominent trend gaining traction in the transcatheter valve repair system market, with key market players actively pursuing the development of innovative products to solidify their market positions. An example of this trend is evident in December 2022 when Abbott Laboratories Inc., a US-based healthcare company, launched the Navitor transcatheter aortic valve implantation (TAVI) system. This latest-generation system, designed to prevent blood leakage around the valve, brings minimally invasive technology to individuals in India suffering from severe aortic stenosis and at high or extreme risk for surgery. This advancement represents Abbott's commitment to progressing TAVI therapies through innovative valve designs.

Major market participants are directing their efforts towards developing advanced technologies, such as the next-generation transcatheter heart valve, to provide improved heart valve replacement options. The next-generation transcatheter heart valve, exemplified by Edwards Lifesciences' SAPIEN 3 Ultra RESILIIA launched in September 2022, incorporates RESILIA tissue technology to address the primary cause of reintervention following heart valve replacement - calcification. This innovation marks a significant step forward in minimally invasive heart valve replacement procedures.

In January 2022, Sahajanand Medical Technologies Limited, an India-based medical device company, acquired Vascular Concepts for an undisclosed amount. This strategic acquisition positions Sahajanand Medical Technologies Limited to enhance its advanced medical technologies by adding aortic valves and transcatheter valve repair systems to its product portfolio. Vascular Concepts, an India-based clinical medical device company, specializes in designing, developing, and manufacturing hydra transcatheter aortic valve systems.

Major companies operating in the transcatheter valve repair system market include Abbott Laboratories, Medtronic Plc., Boston Scientific Corporation, Edwards Lifesciences Corporation, Bracco Group, LivaNova Plc., Meril Life Sciences Pvt. Ltd., Cordis Corporation, MicroPort Scientific Corporation., Biotronik Pvt. Ltd, AtriCure Inc., OrbusNeich Medical Group Holdings Limited, Venus Medtech (Hangzhou) Inc., Dura LLC, HLT Medical Inc., Symetis SA, JenaValve Technology Inc., 4C Medical Technologies Inc., Cardiac Dimensions Inc., Valve Solutions Inc., Transcatheter Technologies GmbH, Evalve Corporation, Colibri Heart Valve LLC, Medtentia International Ltd., Coramaze Technologies Ltd., Neovasc Inc., Anteris Technologies Ltd.

North America was the largest region in the transcatheter valve repair systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transcatheter valve repair system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transcatheter valve repair system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A transcatheter valve repair system constitutes a minimally invasive procedure wherein a catheter is inserted through a small incision in the leg or chest and guided to the heart with the aid of imaging guidance. This approach is employed for treating patients with severe mitral regurgitation (grade 3+ or above) resulting from abnormal mitral valve leaflets and the surrounding region, especially when open-heart surgery is deemed excessively risky.

The primary products associated with the transcatheter valve repair system include transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter pulmonary valve replacement (TPVR), and transcatheter tricuspid valve replacement (TTVR). Transcatheter Aortic Valve Replacement (TAVR) specifically pertains to the replacement of an aortic valve afflicted with stenosis through a minimally invasive cardiac procedure. This method is applied to enhance blood flow and alleviate symptoms associated with aortic valve stenosis, such as fatigue, shortness of breath, fainting, and chest pain. The applications of transcatheter valve repair systems extend to aortic stenosis, mitral stenosis, tricuspid stenosis, and pulmonary stenosis, with utilization in hospitals, specialty clinics, ambulatory surgical centers, and other medical facilities.

The transcatheter valve repair system treatment market research report is one of a series of new reports that provides transcatheter valve repair system treatment market statistics, including the transcatheter valve repair system treatment industry's global market size, regional shares, competitors with an transcatheter valve repair system treatment market share, detailed transcatheter valve repair system treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the transcatheter valve repair system treatment industry. This transcatheter valve repair system treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The transcatheter valve repair systems market includes revenues earned by entities by providing mitraClip G4 system, NeoChord, harpon, and PaScal precision transcatheter. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.